Merck & Co., Inc. (0QAH.L)
| Previous close | N/A |
| Open | 74.85 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 74.85 - 74.85 |
| 52-week range | 74.85 - 74.85 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 27.03 |
| EPS (TTM) | 2.77 |
| Earnings date | 27 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC
- Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored
- Business Wire
Merck to Present at the Barclays 2023 Global Healthcare Conference
RAHWAY, N.J., March 08, 2023--Merck to Present at the Barclays 2023 Global Healthcare Conference
